The expression of anamorsin in diffuse large B cell lymphoma: possible prognostic biomarker for low IPI patients

Leukemia & Lymphoma
Takae ShizusawaYuzuru Kanakura

Abstract

Anamorsin is a cell-death-defying factor, which was originally isolated as a molecule that conferred resistance to apoptosis induced by growth factor starvation. In order to evaluate anamorsin expression levels in malignant lymphoma, we immunostained paraffin-embedded sections with anti-anamorsin monoclonal antibodies. About 40% (89/234) of sections from patients with diffuse large B cell lymphoma (DLBCL) showed strong anamorsin expression. Comparing the level of anamorsin expression in DLBCL patients with their clinical features (i.e., overall survival rate, International Prognostic Index (IPI) parameters, and treatment response) revealed no significant correlation between anamorsin expression levels and these clinical features. However, anamorsin expression in DLBCL patients with a low IPI was shown to be an unfavorable biomarker, especially in the patients who received chemotherapy without rituximab. It is suggested that anamorsin might play some roles in the abnormal growth of DLBCL.

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Mar 1, 2002·The New England Journal of Medicine·David G Savage, Karen H Antman
Oct 1, 2003·Pathology International·Yutaka HatanakaYoichi Tani
Feb 19, 2004·The Journal of Experimental Medicine·Hirohiko ShibayamaYuzuru Kanakura
Aug 18, 2004·Current Opinion in Oncology·Randy D Gascoyne
Mar 24, 2005·Blood Reviews·Asher Chanan-Khan
Jul 15, 2005·The New England Journal of Medicine·Daniela S Krause, Richard A Van Etten
Jan 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Javeed IqbalWing C Chan
Jan 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Izidore S Lossos, Daniel Morgensztern
Jun 27, 2006·Clinical Lymphoma & Myeloma·Latha Shivakumar, James O Armitage
Aug 24, 2006·Expert Review of Anticancer Therapy·Gerhard HeldMichael Pfreundschuh
Oct 10, 2006·Seminars in Hematology·Owen A O'Connor, Paul Hamlin

❮ Previous
Next ❯

Citations

Jun 21, 2012·World Journal of Surgical Oncology·Xiaolan CaiXiaoyan Xin
Apr 7, 2010·Expert Opinion on Therapeutic Targets·Xiaohua LiDaiming Fan
Apr 26, 2011·Biochemical and Biophysical Research Communications·Yuri SaitoYuzuru Kanakura
Jan 12, 2011·Biochemical and Biophysical Research Communications·Yuri SaitoYuzuru Kanakura
Jun 22, 2012·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Dan LuXuemei Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.